CYGNUS TECHNOLOGIES – Trademark Portfolio

Entity Type: 16

CYGNUS TECHNOLOGIES holds 6 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 3 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 2 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include MOCKV and ENDONUCLEASEGTP. The owner is based in SOUTHPORT, NC.

4332 SOUTHPORT SUPPLY ROAD, SE

SOUTHPORT, NC 28461

6 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

CYGNUS TECHNOLOGIES's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

1
Chemicals (3 filings)

Chemical products for industry, science, photography, agriculture, horticulture and forestry

42
Computer & Scientific (3 filings)

Scientific and technological services; industrial analysis and research services

Frequently Asked Questions

How many trademarks does CYGNUS TECHNOLOGIES have?

CYGNUS TECHNOLOGIES has 6 U.S. trademarks filed with the USPTO. Of these, 2 registered, 4 abandoned.

What trademark classes does CYGNUS TECHNOLOGIES file in?

CYGNUS TECHNOLOGIES files trademarks across 2 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 42 (Computer & Scientific). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.

What are CYGNUS TECHNOLOGIES's most well-known trademarks?

CYGNUS TECHNOLOGIES's registered trademark portfolio includes well-known marks such as MOCKV and ENDONUCLEASEGTP. These are among 2 currently registered trademarks in the portfolio.

What is CYGNUS TECHNOLOGIES's trademark registration success rate?

CYGNUS TECHNOLOGIES has a 33% trademark registration rate, with 2 out of 6 resolved applications resulting in successful registration. Currently, 0 applications are pending review.